Citations

Mayo Clinic

Showing 10 of 108551 citations.

Bioactive Moldable Click Chemistry Polymer Cement with Nano-Hydroxyapatite and Growth Factor-Enhanced Posterolateral Spinal Fusion in a Rabbit Model
Liu, Xifeng , Potes, Maria Astudillo , Dashtdar, Babak , Schreiber, Areonna , Rezaei, Asghar , Miller, A. Lee , Elder, Benjamin D. , Lu, Lichun , Astudillo Potes, Maria D, Serdiuk, Vitalii , Schreiber, Areonna C , Miller, Alan Lee , Shafi, Mahnoor , Lu, Lichun , Hamouda, Abdelrahman M.

ACS Applied Bio Materials | March 19, 2024 | Volume: 7 | Issue: 4 | Pages: 2450-2459

10.1021/acsabm.4c00073 | PMID 38500414 Get It

The occurrence of mental health symptoms in isotretinoin‐treated adolescents
Miller, Keith A. , McKean, Alastair J. , Hand, Jennifer L. , Rackley, Sandra , Leung, Jonathan G. , Geske, Jennifer R. , Bostwick, John , Miller, Keith , McKean, Alastair, Geske, Jennifer, Bostwick, J Michael, Leung, Jonathan G , Geske, Jennifer , LeMahieu, Allison

Pediatric Dermatology | March 19, 2024 | Volume: 41 | Issue: 4 | Pages: 635-640

10.1111/pde.15595 | PMID 38500340 Get It

AbstractBackgroundIsotretinoin treatment for acne can reduce adverse psychiatric outcomes in adults, but there has been little investigation of the incidence of psychiatric outcomes in treated adolescents.MethodsThis retrospective cohort study using the Rochester Epidemiology Project identified 606 patients aged 12–18 prescribed isotretinoin over a 10‐year period between January 1, 2008 and December 31, 2017. Medical records were reviewed to identify psychiatric diagnoses before and during isotretinoin therapy, as well as psychiatric symptoms not captured by formal diagnoses and changes to isotretinoin dosing because of psychiatric diagnoses or symptoms.ResultsOne hundred seventy‐seven (29.2%) had a psychiatric diagnosis prior to isotretinoin initiation, but 98 (16.2%) had a new psychiatric diagnosis or psychiatric symptom while taking isotretinoin. Patients with a psychiatric history were no more likely than those without to receive a new psychiatric diagnosis during treatment (4.5% vs. 3.7%; p = .650), but did experience more psychiatric symptoms, primarily low mood and mood swings (23.7% vs. 7.7%; p < .001). Only 25.5% of the 98 with a new psychiatric diagnosis or psychiatric symptom had a subsequent dose change. A dose change was more likely if patients received a new psychiatric diagnosis (41.7% vs. 20.3%; p = .037) or patients did not have a psychosocial explanation for psychiatric symptoms (34.4% vs. 10.8%; p = .009).ConclusionsA substantial proportion of adolescent patients prescribed isotretinoin had a prior psychiatric diagnosis. This predicts more psychiatric symptoms during isotretinoin treatment. Adolescents with a psychiatric history who have worsening symptoms and those with new‐onset psychiatric symptoms would benefit from close monitoring while taking isotretinoin.
In Silico Investigation of Parkin-Activating Mutations Using Simulations and Network Modeling
Islam, Naeyma N., Weber, Caleb A., Coban, Matt , Cocker, Liam T. , Fiesel, Fabienne C. , Springer, Wolfdieter , Caulfield, Thomas R , Coban, Mathew A , Fiesel, Fabienne C , Springer, Wolfdieter , Caulfield, Thomas R.

Biomolecules | March 19, 2024 | Volume: 14 | Issue: 3 | Pages: 365

10.3390/biom14030365 | PMID 38540783 Get It

Complete loss-of-function mutations in the PRKN gene are a major cause of early-onset Parkinson’s disease (PD). PRKN encodes the Parkin protein, an E3 ubiquitin ligase that works in conjunction with the ubiquitin kinase PINK1 in a distinct quality control pathway to tag damaged mitochondria for autophagic clearance, i.e., mitophagy. According to previous structural investigations, Parkin protein is typically kept in an inactive conformation via several intramolecular, auto-inhibitory interactions. Here, we performed molecular dynamics simulations (MDS) to provide insights into conformational changes occurring during the de-repression of Parkin and the gain of catalytic activity. We analyzed four different Parkin-activating mutations that are predicted to disrupt certain aspects of its auto-inhibition. All four variants showed greater conformational motions compared to wild-type protein, as well as differences in distances between domain interfaces and solvent-accessible surface area, which are thought to play critical roles as Parkin gains catalytic activity. Our findings reveal that the studied variants exert a notable influence on Parkin activation as they alter the opening of its closed inactive structure, a finding that is supported by recent structure- and cell-based studies. These findings not only helped further characterize the hyperactive variants but overall improved our understanding of Parkin’s catalytic activity and nominated targets within Parkin’s structure for potential therapeutic designs.
Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future
Abbas, Mohammed Tiseer , Ali, Nima Baba , Farina, Juan M. , Mahmoud, Ahmed , Pereyra, Milagros , Scalia, Isabel G. , Kamel, Moaz, Barry, Timothy , Lester, Steven J., Cannan, Charles R., Mital, Rohit , Wilansky, Susan , Freeman, William K., Alsidawi, Said , Arsanjani, Reza , Baba Ali, Nima, Kamel, Moaz A, Alsidawi, Said , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Mahmoud, Ahmed K , Scalia, Isabel G , Abbas, Mohammed Tiseer , Chao, Chieh‐Ju

Biomedicines | March 19, 2024 | Volume: 12 | Issue: 3 | Pages: 682

10.3390/biomedicines12030682 | PMID 38540296 Get It

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. It follows an autosomal dominant inheritance pattern in most cases, with incomplete penetrance and heterogeneity. It is familial in 60% of cases and most of these are caused by pathogenic variants in the core sarcomeric genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1). Genetic testing using targeted disease-specific panels that utilize next-generation sequencing (NGS) and include sarcomeric genes with the strongest evidence of association and syndrome-associated genes is highly recommended for every HCM patient to confirm the diagnosis, identify the molecular etiology, and guide screening and management. The yield of genetic testing for a disease-causing variant is 30% in sporadic cases and up to 60% in familial cases and in younger patients with typical asymmetrical septal hypertrophy. Genetic testing remains challenging in the interpretation of results and classification of variants. Therefore, in 2015 the American College of Medical Genetics and Genomics (ACMG) established guidelines to classify and interpret the variants with an emphasis on the necessity of periodic reassessment of variant classification as genetic knowledge rapidly expands. The current guidelines recommend focused cascade genetic testing regardless of age in phenotype-negative first-degree relatives if a variant with decisive evidence of pathogenicity has been identified in the proband. Genetic test results in family members guide longitudinal clinical surveillance. At present, there is emerging evidence for genetic test application in risk stratification and management but its implementation into clinical practice needs further study. Promising fields such as gene therapy and implementation of artificial intelligence in the diagnosis of HCM are emerging and paving the way for more effective screening and management, but many challenges and obstacles need to be overcome before establishing the practical implications of these new methods.
Rare Presentation of Papillary Carcinoma Within a Sentinel Lymph Node in a Patient With Ductal Carcinoma in Situ of the Breast: A Challenging but Useful Case Report Discussion Regarding Displacement or True Metastasis?
Sonam, Fnu , Jakub, James W. , Cornell, Lauren , Robinson, Kristin A. , Komforti, Miglena K. , Jakub, James W , Robinson, Kristin A , Fnu, Sonam , Cornell, Lauren F

International Journal of Surgical Pathology | March 19, 2024 | Volume: 32 | Issue: 8 | Pages: 1588-1594

10.1177/10668969241235316 | PMID 38500348 Get It

Papillary carcinoma of the breast is a rare histologic subtype of invasive breast cancer. In contrast, ductal carcinoma in situ (DCIS) is a noninvasive, nonobligate precursor to invasive mammary carcinoma, confined within the terminal duct lobular unit of the breast and surrounded by an intact myoepithelial cell layer at the stromal/epithelial interface. We present an unusual case in which a patient with only DCIS of the breast exhibited papillary carcinoma within a sentinel lymph node, leading to questions about the origin of the lymph node lesion—whether it represents a true metastasis or iatrogenic displacement during diagnostic procedures. This case underscores the diagnostic challenges and clinical implications associated with such rare presentations.
Effect of a Multidisciplinary Review Panel on Daily Morphine Milligram Equivalents for Patients With Chronic Pain
Kauppila, Glenn , Strahm, Sarah M. , Vogel, Erica L., Raap, Stephanie M., Cash, Dana H., Yost, Kaitlin J. , Kauppila, Glenn R

Journal of Primary Care & Community Health | March 19, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241240345 | PMID 38500333 Get It

Introduction/Objective: Physicians and other health care professionals are challenged regularly to balance managing pain for patients with chronic pain receiving chronic opioid therapy (COT) with following the national guidelines and standards regarding daily morphine milligram equivalents (MME). This quality improvement project aimed to determine the effect of referral to a multidisciplinary review panel on daily MME for patients receiving COT for chronic pain. Methods: This quality improvement project included patients who had an established relationship with a primary care or community internal medicine clinician at a large health care organization and were referred to a newly created multidisciplinary review panel for their recommendations regarding treatment of pain. Criteria for patient referral were diagnosis of a chronic, painful condition, and use of chronic opioid medications. These patients were selected and referred at the discretion of their primary care clinician from January 2, 2019, through December 31, 2020. Data for this project were collected at the time of initial referral to the panel and 6 months after recommendations. The daily MME were assessed at the 2 time points. Results: Thirteen patients were referred to the review panel during the project period. The median daily MME at the time of referral was 180. Daily MME decreased by a median of 14 MME after 6 months. The MME did not increase during the project period for any participants. Conclusions: Referral of patients receiving COT to a multidisciplinary review panel may reduce their daily opioid dose.
Evaluation of Sonicate Fluid Culture Cutoff Points for Periprosthetic Joint Infection Diagnosis
Otero, Judith Álvarez , Karau, Melissa J. , Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jay , Patel, Robin , Alvarez Otero, Judith, Patel, Robin , Abdel, Matthew P.

Open Forum Infectious Diseases | March 19, 2024 | Volume: 11 | Issue: 5 | Pages: No page available

10.1093/ofid/ofae159 | PMID 38715572 Get It

Abstract Introduction Implant sonication is useful for recovery of periprosthetic joint infection (PJI) pathogens in culture, but exact cutoff points for definition of clinically significant sonicate fluid culture results vary from study to study. The aim of this study was to define ideal sonicate fluid culture cutoff points for PJI diagnosis. Methods Sonicate fluid cultures from hip and knee prosthesis components removed between February 2007 and December 2020 were studied. Prosthesis components were placed in solid containers in the operating room; in the clinical microbiology laboratory, 400 mL Ringer's solution was added, and containers subjected to vortexing, sonication and then vortexing, followed by centrifugation. Concentrated sonicate fluid was plated on aerobic and anaerobic solid media, and culture results reported semiquantitatively, as no growth, &lt;20, 20–50, 51–100, or &gt;100 CFU/10 mL sonicate fluid. Sonicate cultures from cement spacers and cultures yielding more than 1 microorganism were excluded. Sensitivity and specificity of each cutoff point was evaluated. Results A total of 1448 sonicate fluid cultures were evaluated, 68% from knees and 32% from hips. PJI was present in 644 (44%) cases. Sensitivity of sonicate culture was 75.0% at &lt;20 CFU/10 mL, 55.3% at ≥20 CFU/10 mL, 46.9% at &gt;51 CFU/10 mL, and 39.8% at &gt;100 CFU/10 mL. Specificity was 78.2%, 99.8%, 100%, and 100%, at the 4 cutoff points, respectively. Conclusions A cutoff point for sonicate fluid culture positivity of ≥20 CFU/10 mL is suitable for PJI diagnosis.
Revisiting Race, Ethnicity, and Disparities in Rheumatology Educational Materials: An Update Since 2020
Zickuhr, Lisa , Roberts, Eric T. , Daugherty, Tyler, Rana, Amaad , Joshi, Hirva, Pollard, Bruin , Yu, Jonathan , Jones, Heather , Goglin, Sarah , Roberts, Eric

Arthritis Care & Research | March 19, 2024 | Volume: 76 | Issue: 7 | Pages: 1045-1049

10.1002/acr.25326 | PMID 38499988 Get It

ObjectiveIn 2020, one study by Strait and colleagues raised awareness that the clinical images in rheumatology educational materials underrepresent people with skin of color (P‐SOC). Since then, publishers of rheumatology educational materials have focused on addressing this shortcoming. This study investigates the change in representation of P‐SOC following the review of Strait et al.MethodsWe used the methods of the aforementioned study to collect images from commonly referenced rheumatology educational materials and categorized the skin tones within them as “light” or “dark.” We calculated the proportional change in images depicting dark skin tones between 2020 and 2022 from the American College of Rheumatology (ACR) Image Library, the 10th edition of Kelley's Textbook of Rheumatology, and New England Journal of Medicine (NEJM) as well as between 2020 and 2024 from rheumatology articles within UpToDate. We compared results using one‐sided Z‐tests.ResultsOverall, the proportion of images depicting dark skin tones increased 40.6% (P < 0.0001). The 10th edition of Kelley's Textbook of Rheumatology most significantly increased inclusion of P‐SOC (90.1%; P = 0.0039), with ACR Image Library, UpToDate, and NEJM also enhancing representation (41.9%, P < 0.0001; 31.0%, P = 0.0083; 28.2%, P = 0.3046, respectively).ConclusionThis study assesses the progress of rheumatology educational materials toward equitable representation of P‐SOC. It demonstrates that awareness coupled with focused efforts from educational publishers can enhance the proportion of images depicting dark skin tones, thereby enriching the quality of foundational knowledge relayed to rheumatology providers with the goal of improving health experiences and outcomes for P‐SOC with rheumatic diseases.image
Neurological Care within the Indian Health Service
Parko, Karen, Stitzer, Michael, Trimble, Brian, Christensen, Loretta , Stitzer, Michael E.

Seminars in Neurology | March 19, 2024 | Volume: 44 | Issue: 02 | Pages: 205-216

10.1055/s-0044-1782517 | PMID 38499194 Get It

AbstractAmerican Indians and Alaska Natives (AI/AN) are the Indigenous peoples of the United States. According to the U.S. Census Bureau, approximately 9.7 million people self-identified as AI/AN (alone or in combination with other races), representing 2.9% of the total U.S. population. These people represent diverse groups of discrete Tribes, each with their language, culture, and geographic home. As part of the conquest and settlement of North America, some Indigenous peoples signed treaties with the U.S. government, surrendering their lands in return for various government commitments, including health care. The Indian Health Service (IHS) was born out of these agreements. The IHS is an agency in the U.S. Department of Health and Human Services under the U.S. Public Health Service. The IHS provides a comprehensive health service delivery system for approximately 2.7 million AI/AN who belong to 574 federally recognized Tribes/nations in 37 states. The aim of this paper is to make recommendations regarding the initiation of sustainable neurology care in marginalized or underserved populations by reviewing 40 years of neurology care provision within the IHS. We will discuss (1) the IHS, (2) neurological care provided within the IHS, including midlevel provider extension of neurology care and traditional medical care, and (3) select neurological diagnoses within AI/AN populations. Marginalized populations, including those in the United States that are rural, remote, or low socioeconomic status, lack access to specialty neurology care. This includes many AI/AN. The IHS has developed novel solutions to promote specialty care, including neurology. Notably, initial IHS investments in full-time neurology providers have led to more robust neurology care, often receiving attention from university programs. This suggests that an initial investment in stable on-site full-time neurology services provides a path to potential sustainable care for marginalized populations.
Mesothelioma: Pleural, Version 1.2024
Stevenson, James, Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Garassino, Marina Chiara , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Otterson, Gregory A. , Owen, Dawn , Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Journal of the National Comprehensive Cancer Network | March 18, 2024 | Volume: 22 | Issue: 2 | Pages: 72-81

10.6004/jnccn.2024.0014 | PMID 38503043 Get It

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.